Biovica International
2,615
SEK
-2,06 %
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 investor følger denne virksomhed
-2,06%
+19,68%
+0,58%
+3,36%
+1,36%
-0,57%
-92,11%
-75,23%
-76,48%
biovica.com/investor-relations
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Omsætning
7,29 mio.
EBIT %
-1.740,05 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
BIOVIC B
Daglig lav / høj pris
2,53 / 2,765
SEK
Markedsværdi
255,71 mio. SEK
Aktieomsætning
313,36 t SEK
Volumen
118 t
Seneste videoer
Finanskalender
Delårsrapport
12.12.2024
Delårsrapport
13.03.2025
Årsrapport
19.06.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Anders Rylander Investment AB | 10,9 % | 17,0 % |
Avanza Pension | 5,0 % | 4,4 % |
Nordnet Pension Insurance | 3,7 % | 3,2 % |
Mattias Sesemann | 3,5 % | 3,1 % |
Mats Danielsson | 3,3 % | 2,9 % |
Handelsbanken Life Insurance AB | 3,2 % | 2,8 % |
Britta Ingeborg Rylander | 1,8 % | 3,4 % |
Lars Holmqvist | 1,6 % | 1,4 % |
Gunvald Berger | 1,4 % | 1,3 % |
Göran Brorsson | 1,2 % | 1,1 % |
ViserAlle indholdstyper
New DiviTum® TKa data to be presented at SABCS that significantly broaden the addressable market
Biovica signs agreement with UK biotech company
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools